India & Abbott Laboratories
18 shared events · Importance 6 · Last updated Aug 21, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Business
India: India is a key country in the MSCI Asia Pacific Index region, which is witnessing rapid market growth due to increasing healthcare investments and expanding laboratory infrastructure.
Abbott Laboratories: As a major player in the CLIA market, Abbott Laboratories is strengthening its market position through innovation and strategic collaborations, with its ARCHITECT and Alinity i systems playing a major role in advancing high-throughput immunodiagnostic testing globally.
Jun 05, 2026 · 6 articles
Business
India: Domestic market; semaglutide supplies unavailable in India until late October, affecting local availability.
Abbott Laboratories: Central company; reported 69% profit plunge, made Rs 240 crore provision, delayed semaglutide supplies, and faces securities investigation. Shares fell sharply.
Jul 09, 2026 · 23 articles
Business
India: The partnership strengthens India's pharmaceutical manufacturing capabilities, with both companies based in Hyderabad and the new facility in Visakhapatnam, contributing to the country's position as a global pharma hub.
Abbott Laboratories: Neuland gains dedicated sterile API manufacturing capacity through Gland Pharma, supporting its growing demand and enhancing its CDMO capabilities. The corporate guarantee of ₹40 crore reflects its commitment.
Aug 05, 2026 · 6 articles
Business
India: Senior population projected to reach 230 million by 2036, boosting demand.
Abbott Laboratories: Key player; strong in in vitro diagnostics, the largest segment.
Jul 21, 2026 · 8 articles
Business
India: Emerging market; partnership with Agappe.
Abbott Laboratories: Key player; market growth supports its diagnostics portfolio.
Jul 08, 2026 · 6 articles
Regulatory
India: India is the country where the approval was granted; the decision addresses a significant public health burden of fatty liver disease.
Abbott Laboratories: Dr. Reddy's produces lower-cost generic semaglutide; the approval may pressure its market share in the obesity segment.
Jul 17, 2026 · 13 articles
Regulatory
India: The approval highlights India's growing role in pharmaceutical innovation, potentially boosting its 'pharmacy of the world' status.
Abbott Laboratories: Already a customer of Pulse's manufacturing, the approval may strengthen their supply relationship.
Aug 20, 2026 · 6 articles
Business
India: India is the home country of Abbott Laboratories, which became the first pharmaceutical company in Asia, outside Japan, to list on the New York Stock Exchange.
Abbott Laboratories: Abbott Laboratories is celebrating 25 years of its listing on the New York Stock Exchange, reaffirming its commitment to global governance, transparency, and innovation, and highlighting its trusted presence in the US pharmaceutical market.
May 28, 2026 · 7 articles
Business
India: India is a key battleground for weight-loss drugs due to its large obesity population and is experiencing significant competition between Novo Nordisk and Eli Lilly and Company.
Abbott Laboratories: Abbott Laboratories is one of several Indian generic drugmakers poised to enter the market with lower-priced versions of semaglutide once Semaglutide loses patent exclusivity.
Nov 11, 2025 · 6 articles
Accidents
India: India is partnering with the United States — Centers for Disease Control and Prevention to deliver medical supplies to aid in the Ebola response.
Abbott Laboratories: Abbott Laboratories is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.
May 15, 2026 · 446 articles
Business
India: The IPO is part of India's active primary market, contributing to the country's capital markets development.
Abbott Laboratories: As a listed peer, Divi's Laboratories may face competitive comparisons but is not directly impacted.
Aug 19, 2026 · 8 articles
Business
India: The event highlights growth in India's BPC manufacturing ecosystem.
Abbott Laboratories: Partners with Naturis for cosmeceuticals.
Jul 16, 2026 · 6 articles
Business
India: India is added to the NIFTY 50, which may boost its stock.
Abbott Laboratories: Abbott Laboratories was also considered for NIFTY 50 but did not qualify. No direct impact from this review.
Aug 10, 2026 · 7 articles
Business
India: Sensex nearly unchanged.
Abbott Laboratories: Rose up to 11.8% after beating earnings and raising forecast.
Apr 20, 2026 · 344 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how India and Abbott Laboratories interact across events, view sentiment trends, and discover connected entities.
Open Dashboard